Online inquiry

IVTScrip™ mRNA-Anti-MSLN, BAY 94-9343(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3707MR)

This product GTTS-WQ3707MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets MSLN gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001177355.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 10232
UniProt ID Q13421
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MSLN, BAY 94-9343(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ3707MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6957MR IVTScrip™ mRNA-Anti-VEGFA, ESBA-1008(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ESBA-1008
GTTS-WQ387MR IVTScrip™ mRNA-Anti-TYRP1, 20D7S(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA 20D7S
GTTS-WQ8104MR IVTScrip™ mRNA-Anti-TNFRSF10B, HGS-ETR2(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA HGS-ETR2
GTTS-WQ12223MR IVTScrip™ mRNA-Anti-TNFRSF4, MOXR-0916(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MOXR-0916
GTTS-WQ12395MR IVTScrip™ mRNA-Anti-CD3E, NI-0401(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA NI-0401
GTTS-WQ5907MR IVTScrip™ mRNA-Anti-IL31RA, CIM 331(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CIM 331
GTTS-WQ10384MR IVTScrip™ mRNA-Anti-TNFSF13B, LY2127399(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA LY2127399
GTTS-WQ7083MR IVTScrip™ mRNA-Anti-FAP, FAP-IL2v(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA FAP-IL2v
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW